D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Duopharma Biotech Bhd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Duopharma Biotech Bhd
Long-Term Debt Peer Comparison

Comparables:
P
PLABS
A
AHEALTH
R
RHONEMA
Y
YSPSAH
K
KOTRA

Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Long-Term Debt
myr472.8m
CAGR 3-Years
20%
CAGR 5-Years
29%
CAGR 10-Years
N/A
P
PeterLabs Holdings Bhd
KLSE:PLABS
Long-Term Debt
myr2.3m
CAGR 3-Years
-19%
CAGR 5-Years
18%
CAGR 10-Years
-3%
A
Apex Healthcare Bhd
KLSE:AHEALTH
Long-Term Debt
myr5.9m
CAGR 3-Years
3%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Long-Term Debt
myr21.5m
CAGR 3-Years
-9%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Long-Term Debt
myr36.1m
CAGR 3-Years
11%
CAGR 5-Years
-2%
CAGR 10-Years
11%
K
Kotra Industries Bhd
KLSE:KOTRA
Long-Term Debt
myr82k
CAGR 3-Years
-77%
CAGR 5-Years
-70%
CAGR 10-Years
-50%

See Also

What is Duopharma Biotech Bhd's Long-Term Debt?
Long-Term Debt
472.8m MYR

Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Long-Term Debt amounts to 472.8m MYR.

What is Duopharma Biotech Bhd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
29%

Over the last year, the Long-Term Debt growth was 74%. The average annual Long-Term Debt growth rates for Duopharma Biotech Bhd have been 20% over the past three years , 29% over the past five years .

Back to Top